Pde10a cDNA ORF clone, Rattus norvegicus(Norway rat)

Quantitative Proteomic Study Reveals Up-Regulation of cAMP Signaling Pathway-Related Proteins in Mild Traumatic Brain Injury.
Song H, Fang S, Gao J, Wang J, Cao Z, Guo Z, Huang Q, Qu Y, Zhou H, Yu J
Journal of proteome research(2017 Dec)

Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.
Diggle CP, Sukoff Rizzo SJ, Popiolek M, Hinttala R, Sch?lke JP, Kurian MA, Carr IM, Markham AF, Bonthron DT, Watson C, Sharif SM, Reinhart V, James LC, Vanase-Frawley MA, Charych E, Allen M, Harms J, Schmidt CJ, Ng J, Pysden K, Strick C, Vieira P, Mankinen K, Kokkonen H, Kallioinen M, Sormunen R, Rinne JO, Johansson J, Alakurtti K, Huilaja L, Hurskainen T, Tasanen K, Anttila E, Marques TR, Howes O, Politis M, Fahiminiya S, Nguyen KQ, Majewski J, Uusimaa J, Sheridan E, Brandon NJ
American journal of human genetics98(4)735-43(2016 Apr)

Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.
Wilson JM, Ogden AM, Loomis S, Gilmour G, Baucum AJ 2nd, Belecky-Adams TL, Merchant KM
Neuropharmacology99379-86(2015 Dec)

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
Yang SW, Smotryski J, McElroy WT, Tan Z, Ho G, Tulshian D, Greenlee WJ, Guzzi M, Zhang X, Mullins D, Xiao L, Hruza A, Chan TM, Rindgen D, Bleickardt C, Hodgson R
Bioorganic & medicinal chemistry letters22(1)235-9(2012 Jan)

Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.
Andr?s JI, De Angelis M, Alc?zar J, Iturrino L, Langlois X, Dedeurwaerdere S, Lenaerts I, Vanhoof G, Celen S, Bormans G
Journal of medicinal chemistry54(16)5820-35(2011 Aug)

Through a combination of pharmacological and genetic tools, study provides convergent evidence of D2 (rather than D1) pathway dominant effects of PDE10A inhibition in rodents
Title: Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.

analysis of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia in the rat model
Title: Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.

Data show that pyridinyl derivatives were less potent than their quinolinyl counterparts, but still exhibited significant PDE10A inhibition potency.
Title: Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.

Dopamine loss inversely regulates PDE10A gene expression in the striatum and PDE10A post-transcription in the nucleus accumbens, therein differentially modulating PDE10A-dependent cyclic AMP catabolism.
Title: PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.

The present study is the first to demonstrate a central role of PDE10A in progressive pulmonary vascular remodeling.
Title: Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling.